Cargando…
Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy
Neoadjuvant therapy (NAT) treats early‐stage breast cancers, especially triple‐negative breast cancers (TNBCs). NAT improves pathological complete response (pCR) rates for different breast cancer patients. Recently, immune checkpoint inhibitors that target programmed death 1 (PD‐1) or programmed dea...
Autores principales: | Han, Mengxue, Li, Jinze, Wu, Si, Wu, Chun, Yu, Yongqiang, Liu, Yueping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939127/ https://www.ncbi.nlm.nih.gov/pubmed/36073303 http://dx.doi.org/10.1002/cam4.5207 |
Ejemplares similares
-
Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer
por: Yu, Yongqiang, et al.
Publicado: (2021) -
Reconstructing virtual large slides can improve the accuracy and consistency of tumor bed evaluation for breast cancer after neoadjuvant therapy
por: Han, Dandan, et al.
Publicado: (2022) -
Artificial intelligence-assisted interpretation of Ki-67 expression and repeatability in breast cancer
por: Li, Lina, et al.
Publicado: (2022) -
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
por: Zhang, Huiru, et al.
Publicado: (2022) -
The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
por: Urueña, Claudia, et al.
Publicado: (2022)